Status of prophylactic and therapeutic genital herpes vaccines

Current Opinion in Virology

Volumn 6, Issue 1, 2014, Pages 6-12

  Awasthi, Sita ^a   Friedman, Harvey M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENITAL HERPES VACCINE; HERPES SIMPLEX VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; CLINICAL TRIAL (TOPIC); GENITAL HERPES; HUMAN; NONHUMAN; PIPELINE; PRIORITY JOURNAL; PROPHYLAXIS; STUDY DESIGN; ANIMAL; DISEASE MODEL; FEMALE; HERPES GENITALIS; IMMUNOLOGY; MALE; SIMPLEXVIRUS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HUMANS; MALE; SIMPLEXVIRUS;

EID: 84896517973     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2014.02.006     Document Type: Review

References (78)

1. D.L. Rock et al. Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1 J Virol 61 1987 3820 3826
2. R.J. Whitley, and B. Roizman Herpes simplex virus infections Lancet 357 2001 1513 1518
3. R.B. Belshe et al. Efficacy results of a trial of a herpes simplex vaccine N Engl J Med 366 2012 34 43
4. F.M. Cowan et al. Herpes simplex virus type 1 infection: a sexually transmitted infection of adolescence? Sex Transm Infect 78 2002 346 348
5. K.J. Looker, G.P. Garnett, and G.P. Schmid An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection Bull World Health Organ 86 2008 805 812
6. Y. Xu, M.R. Sternberg, B.J. Kottiri, G.M. McQuillan, F.K. Lee, A.J. Nehmias, S.M. Barman, and L.E. Markowitz Trends in herpes simplex type 1 and type 2 seroprevalence in the United States JAMA 296 2006 964 973
7. L. Corey, and A. Wald Maternal and neonatal herpes simplex virus infections N Engl J Med 361 2009 1376 1385
8. D.W. Kimberlin et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections Pediatrics 108 2001 230 238
9. C. Gardella, H.H. Handsfield, and R. Whitley Neonatal herpes - the forgotten perinatal infection Sex Transm Dis 35 2008 22 24
10. D.J. Rouse, and J.S.A. Stringer An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes Am J Obstet Gynecol 183 2000 400 406
11. T.D. Szucs, B. Karin, D.N. Fisman, and S. Harbarth The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches BMC Infect Dis 1 2001 5 10.1186/1471-2334-1-5
12. E.E. Freeman et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies AIDS 20 2006 73 83
13. E.E. Freeman et al. Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics [Erratum appears in Sex Transm Infect. 2007 Oct;83(6):500] Sex Transm Infect 83 Suppl. 2007 i17 i24
14. B. Romanowski, L. Myziuk, and S. Trottier Seroprevalence of Herpes simplex virus in patients infected with HIV in Canada Proceedings of the 17th international society for sexually transmitted diseases research Seattle 2007
15. E.W. Hook 3rd et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals J Infect Dis 165 1992 251 255
16. A.L. Cunningham et al. Evolution of recurrent herpes simplex lesions. An immunohistologic study J Clin Invest 75 1985 226 233
17. A.L. Cunningham, and D.E. Dwyer The pathogenesis underlying the interaction of HIV and herpes simplex virus after co-infection J HIV Ther 9 2004 9 13
18. A.D. Raymond et al. Herpesvirus saimiri terminal membrane proteins modulate HIV-1 replication by altering Nef and Tat functions Curr HIV Res 5 2007 79 86
19. G. Palu, L. Benetti, and A. Calistri Molecular basis of the interactions between herpes simplex viruses and HIV-1 Herpes 8 2001 50 55
20. M. Moriuchi et al. Herpes simplex virus infection induces replication of human immunodeficiency virus type 1 Virology 278 2000 534 540
21. A. Wald Synergistic interactions between herpes simplex virus type-2 and human immunodeficiency virus epidemics Herpes 11 2004 70 76
22. S.J. Reynolds, and T.C. Quinn Developments in STD/HIV interactions: the intertwining epidemics of HIV and HSV-2 Infect Dis Clin North Am 19 2005 415 425
23. L. Corey, R. Ashley, H.S.V. Valaciclovir Transmission Study Group Prevention of herpes simplex virus type 2 transmission with antiviral therapy Herpes 11 Suppl. 2004 170A 174A
24. C. Celum et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial Lancet 371 2008 2109 2119
25. R.W. Roest et al. High incidence of genotypic variance between sequential herpes simplex virus type 2 isolates from HIV-1-seropositive patients with recurrent genital herpes J Infect Dis 194 2006 1115 1118
26. H. Sakaoka et al. Demonstration of either endogenous recurrence or exogenous reinfection by restriction endonuclease cleavage analysis of herpes simplex virus from patients with recrudescent genital herpes J Med Virol 46 1995 387 396
27. O.W. Schmidt, K.H. Fife, and L. Corey Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes J Infect Dis 149 1984 645 646
28. Z.A. Brown et al. The acquisition of herpes simplex virus during pregnancy N Engl J Med 337 1997 509 515
29. T. Gebhardt et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus Nat Immunol 10 2009 524 530
30. S.M. Garland et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases N Engl J Med 356 2007 1928 1943
31. T.F. Schwarz, and O. Leo Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature Gynecol Oncol 110 Suppl. 2008 S1 S10
32. J.-P. Bouvet, N. Decroix, and P. Pamonsinlapatham Stimulation of local antibody production: parenteral or mucosal vaccination? Trends Immunol 23 2002 209 213
33. P. Brandtzaeg, and R. Pabst Let's go mucosal: communication on slippery ground Trends Immunol 25 2004 570 577
34. F.N. Toka, S. Suvas, and B.T. Rouse CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1 J Virol 78 2004 13082 13089
35. A.A. Chentoufi et al. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D J Immunol 180 2008 426 437
36. J.E. Knickelbein et al. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency Science 322 2008 268 271
37. J. Zhu et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation J Exp Med 204 2007 595 603
38. S. Divito, T. Cherpes, and R. Hendricks A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency Immunol Res 36 2006 119 126
39. K.M. Khanna, A.J. Lepisto, and R.L. Hendricks Immunity to latent viral infection: many skirmishes but few fatalities Trends Immunol 25 2004 230 234
40. K.R. Mott et al. Level of herpes simplex virus type 1 latency correlates with severity of corneal scarring and exhaustion of CD8+ T cells in trigeminal ganglia of latently infected mice J Virol 83 2009 2246 2254
41. M.N. Oxman et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med 352 2005 2271 2284
42. J.I. Cohen Herpes zoster N Engl J Med 369 2013 255 263
43. K.E. Schmader et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years Clin Infect Dis 54 2012 922 928
44. R.A. Alsallaq et al. Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2 Sex Transm Dis 37 2010 290 297
45. G.P. Garnett Role of herd immunity in determining the effect of vaccines against sexually transmitted disease J Infect Dis 191 Suppl. 2005 S97 S106
46. G.P. Garnett et al. The potential epidemiological impact of a genital herpes vaccine for women Sex Transm Infect 80 2004 24 29
47. E.J. Schwartz, E.N. Bodine, and S. Blower Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines Hum Vaccines 3 2007 231 238
48. E.J. Schwartz, and S. Blower Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines J Infect Dis 191 2005 1734 1746
49. K.M. Khanna et al. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia Immunity 18 2003 593 603
50. S. Awasthi et al. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone J Virol 85 2011 10472 10486
51. S. Awasthi et al. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread J Virol 86 2012 4586 4598
52. N. Bourne et al. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected J Infect Dis 192 2005 2117 2123
53. L.R. Stanberry et al. Recurrent genital herpes simplex virus infection in guinea pigs Intervirology 24 1985 226 231
54. B. Meignier, R. Longnecker, and B. Roizman In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents J Infect Dis 158 1988 602 614
55. K.C. Yim et al. The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies J Virol 79 2005 14632 14639
56. H.P. Huemer et al. Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein Immunology 79 1993 639 647
57. M. Skoberne et al. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs J Virol 87 2013 3930 3942
58. A.G. Langenberg et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [Erratum appears in Ann Intern Med 1995 Sep 1;123(5):395] Ann Intern Med 122 1995 889 898
59. L. Corey et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group JAMA 282 1999 331 340
60. L.R. Stanberry et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes N Engl J Med 347 2002 1652 1661
61. S.E. Straus et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes Lancet 343 1994 1460 1463
62. S.E. Straus et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial J Infect Dis 176 1997 1129 1134
63. G. Casanova et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections Cutis 70 2002 235 239
64. G. de Bruyn et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects Vaccine 24 2006 914 920
65. R.B. Belshe et al. Correlate of immune protection against HSV-1 genital disease in vaccinated women J Infect Dis 2013
66. K.A. Judson et al. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection J Virol 77 2003 12639 12645
67. J.M. Lubinski et al. Herpes simplex virus type 1 IgG Fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo J Virol 85 2011 3239 3249
68. T. Nagashunmugam et al. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor J Virol 72 1998 5351 5359
69. H.M. Friedman et al. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells Nature 309 1984 633 635
70. S. Awasthi, J.M. Lubinski, and H.M. Friedman Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine Vaccine 27 2009 6845 6853
71. X. Lin, J.M. Lubinski, and H.M. Friedman Immunization strategies to block the herpes simplex virus type 1 immunoglobulin G Fc receptor J Virol 78 2004 2562 2571
72. H. Shin, and A. Iwasaki A vaccine strategy that protects against genital herpes by establishing local memory T cells Nature 491 2012 463 467
73. A. Mo et al. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4+ and CD8+ cellular immunity and protective efficacy Vaccine 29 2011 8530 8541
74. A. Wald et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons Vaccine 29 2011 8520 8529
75. E. Tronstein et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection JAMA 305 2011 1441 1449
76. L.A. Morrison, and D.M. Knipe Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1 Virology 220 1996 402 413
77. L.A. Morrison, and D.M. Knipe Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection J Virol 68 1994 689 696
78. Y. Hoshino et al. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs J Infect Dis 200 2009 1088 1095